Q3 2020 Sales Performance

Sales, earnings and cash flow growth in 2019 Group: revenue breakdown 2019 Business Units Vaccines (+19%) £7.2bn (21%) Group £33.8bn (+4%) £17.6bn (52%) Pharma (flat) Total Group operating margin 20.6% Total EPS 93.3p +23% Adjusted Group operating margin 26.6% -1.8%pts Adjusted EPS 123.9p +1% Consumer (+2%) flat £9.0bn (27%) Free cash flow £5.1bn 2019 dividend 80p 2017: £5.7bn Source: GSK Full year 2019 results release - February 2020 All growths at constant exchange rates (CER). Group and Consumer growth rates are proforma. Breakdown percentages are approximate gsk 5

View entire presentation